# A comparative study of bloodstream infections in acute myeloid leukemia according to different phases of treatment: Can we predict the organism?

Preetam Kalaskar, Asha Anand, Harsha Panchal, Apurva Patel, Sonia Parikh, Sandip Shah

#### Abstract

**Introduction:** The treatment of acute myeloid leukemia (AML) consists of induction therapy with anthracyclines and cytarabine followed by two to four cycles of consolidation therapy with high-dose cytarabine after achieving remission. There have been very few studies comparing infections during induction and consolidation. We have analyzed blood cultures of patients with AML during episodes of fever occurring during induction and consolidation, for comparing the bloodstream infections in both the phases. **Materials and Methods:** Blood cultures of patients during febrile episodes were collected from central venous catheters and peripheral blood, both during induction and consolidation therapy of AML. **Results:** The study population included 52 AML patients. During induction, there were 52 episodes of fever and 25 (48%) blood cultures were positive, I5 of these blood cultures reported Gram-negative organisms, 9 reported Gram-positive organisms and I as yeast. During consolidation, 47 episodes of fever were recorded and blood cultures were positive in 12, of which 7 were Gram-negative, 5 were Gram-positive. **Conclusion:** The incidence of blood culture positive infections during therapy of AML at our center was higher. The predominant organism isolated was Gram-negative both during induction and consolidation. The incidence of blood culture positive infections had decreased by 50% during consolidation.

Key words: Acute myeloid leukemia, consolidation, induction

# Introduction

Treatment of acute myeloid leukemia (AML) consists of induction therapy with anthracyclines and cytarabine followed by two to four cycles of consolidation therapy with high-dose cytarabine after achieving remission.<sup>[1]</sup> The induction and consolidation therapies are known to be complicated with infections during neutropenia. Till the late 1960s, Gram-negative infections were predominant infection during therapy of AML. Over the next two to three decades, the predominant infection during therapy changed from Gram-negative to -positive organisms. Recent bloodstream infection rates during induction have been 27.8% and during consolidation phase has been around 25%. The predominant organisms during induction were Gram-positive (80%); those during consolidation were Gram-negative (72%).<sup>[2]</sup> There have been very few Indian studies comparing infections during induction and consolidation. We have analyzed blood cultures of patients with AML during episodes of fever occurring during induction and consolidation therapy at our institute during the years 2014–2015 to compare the infective organisms during induction and consolidation.

# **Materials and Methods**

This is a retrospective analysis carried out at our institute from June 2014 to July 1015. Patients with AML were treated at our institute with induction therapy of daunorubicin  $60 \text{ mg/m}^2$  (days 1–3) and cytarabine (100–200 mg/m<sup>2</sup>) continues infusion over 24 h (days 1–7).<sup>[1]</sup> When the patients developed fever defined as 101°F single-episode or 100.4°F continues for 1 h or more, blood cultures from central venous catheter and peripheral blood were collected along other investigation. Infective episodes were treated as per generally accepted guidelines.<sup>[3]</sup> Those in remission,<sup>[4]</sup> postconsolidation (defined as <5% blast without hypocellularity, no extramedullary disease) were started on



Department of Medical and Pediatric Oncology, Gujarat Cancer and Research Institute Regional Cancer Center, B.J. Medical College, Ahmedabad, Gujarat, India **Correspondence to:** Dr. Asha Anand,

E-mail: ashaanand 1757@yahoo.com

consolidation therapy. Consolidation therapy consisted of high-dose cytarabine (1.5 mg to 3 mg/m<sup>2</sup>)<sup>[5]</sup> over 2–3 h 12 hourly on days 1, 3, and 5. During consolidation, protocol for treating febrile episodes and culture collections were same as per induction.

Patients of AML, other than therapy-related AML, acute promyeloid leukemia, and myelodysplasia-related features, between age group of 18–60 years who achieved induction remission were included in the study.

#### Investigations

On treatment, febrile episodes were investigated with chest X-rays, blood cultures from central catheter, peripheral blood, and urine routine microscopy. Antimicrobial treatment was prescribed as per IDSA recommendations.<sup>[3]</sup>

### **Results**

The study population included 52 AML patients. There were 27 males and 25 females. During induction, there were 52 episodes of fever and 25 (48%) blood cultures were positive. Fifteen of these blood cultures reported Gram-negative organisms, nine reported Gram-positive organisms, and one as yeast. During consolidation, 47 episodes of fever were recorded and blood cultures were positive in 12 (25.53%), of which 7 were Gram-negative, 5 were Gram-positive [Table 1].

#### Discussion

Blood culture positive infections are noted in 65% of patients during AML therapy in India<sup>[6]</sup> and this leads to increase in morbidity, mortality, and cost of therapy by a great margin. The lack of studies on the comparison of organisms during induction and consolidation led to this observational study. Our study shows that the incidence of blood culture-positive infection varied during induction and consolidation. The strength of the study is the detection of organisms with respect to the different

For reprints contact: reprints@medknow.com

**How to cite this article:** Kalaskar P, Anand A, Panchal H, Patel A, Parikh S, Shah S. A comparative study of bloodstream infections in acute myeloid leukemia according to different phases of treatment: Can we predict the organism?. South Asian J Cancer 2017;6:132-3.

© 2017 The South Asian Journal of Cancer | Published by Wolters Kluwer - Medknow

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

| Table 1: The distribution of different Gram-positive and   |  |
|--|--|
| Gram-negative infection during induction and consolidation |  |

|                                  | Number of culture positive (%) |               |  |
|----------------------------------|--------------------------------|---------------|--|
|                                  | Induction                      | Consolidation |  |
| Gram-negative bacteria           | 15 (28.8)                      | 7 (14.89)     |  |
| Escherichia coli                 | 7                              | 3             |  |
| Klebsiella pneumoniae            | 4                              | 3             |  |
| Pseudomonas aeruginosa           | 2                              | 1             |  |
| Burkholderia cepacia             | 2                              | -             |  |
| Gram-positive bacteria           | 9 (17)                         | 5 (10.6)      |  |
| Coagulase negative staphylococci | 4                              | 3             |  |
| Coagulase positive staphylococci | 3                              | 1             |  |
| Enterococcus                     | 2                              | 1             |  |
| Yeast                            | 1                              | -             |  |
| Total                            | 25/52 (48)                     | 12/47 (25.53) |  |




Figure 1: Graphical representation of the distribution of organisms in induction and consolidation

phases of treatment of AML therapy. We had 52 AML patients, who did not receive prophylactic antibiotics during therapy except antifungal in the form of fluconazole. The incidence of blood culture-positive infections during induction was 48%, which is higher compared with studies from the West where it is reported to be 29.6%<sup>[7]</sup> while it is lower compared to data reported from India of 65%.<sup>[6]</sup> During the last few years, there has been a shift from Gram-negative infections to Gram-positive infections during acute leukemia therapy probably related to increased use of intravascular catheters, fluoroquinolone prophylaxis. However, in our study, the incidence of culture positive infections during induction was 48%, of which 60% were caused by Gram-negative organisms, 36% by Gram-positive organisms, and 4% yeast [Figure 1]. During consolidation, the culture positive infections were 25.5%, of which the Gram-negative infections constituted 50%, Gram-positive infections were 41.66%, and polymicrobial infection were reported in only 1 (8.33%) patient, both were gram-negative organisms [Figure 1]. On analyzing the bloodstream infection,

the incidence of blood culture-positive infection was almost double during induction compared to consolidation. Contrary to our assumption, the consolidation would have more of Gram-negative infections compared to induction in view of increased gastrointestinal toxicity of high-dose cytarabine. This could probably be explained by the active disease during induction compared to consolidation. Our result correlates with Indian studies showing predominant Gram-negative infection in cancer patients.<sup>[8]</sup>

# Conclusion

The incidence of blood culture-positive infections during therapy of AML at our center was higher. The predominant organism isolated was Gram-negative during both induction and consolidation. The incidence of blood culture-positive infections had decreased by 50% during consolidation.

# Financial support and sponsorship

Nil.

#### **Conflicts of interest**

There are no conflicts of interest.

#### References

- Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
- Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, *et al.* Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: A report from SWOG and MD Anderson. Leukemia 2014;28:289-92.
- Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:427-31.
- Creutzig U, Kaspers GJ. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2004;22:3432-3.
- Rahman MH, Khan MA, Islam MS, Afrose S, Ara T. High dose cytosine arabinoside in the consolidation of adult acute myeloid leukemia. Mymensingh Med J 2012;21:213-9.
- Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA, *et al.* Acute myeloid leukaemia: Challenges and real world data from India. Br J Haematol 2015;170:110-7.
- De Rosa FG, Motta I, Audisio E, Frairia C, Busca A, Di Perri G, *et al.* Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infect Dis 2013; 13:563.
- Prabhash K, Medhekar A, Ghadyalpatil N, Noronha V, Biswas S, Kurkure P, *et al.* Blood stream infections in cancer patients: A single center experience of isolates and sensitivity pattern. Indian J Cancer 2010;47:184-8.